Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
about
Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014)Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.The changing face of antibiotic prescribing: the mutant selection window.Moxifloxacin in respiratory tract infections.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Mutant selection window hypothesis updated.Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.A unified anti-mutant dosing strategy.Quinolones: action and resistance updated.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacinMutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compoundsPharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Functional analysis of pneumococcal drug efflux pumps associates the MATE DinF transporter with quinolone susceptibilityComparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Advances in pneumococcal antibiotic resistance.beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosaInfluence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513.Low correlation between MIC and mutant prevention concentration.The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.Quinolone resistance among pneumococci: therapeutic and diagnostic implications.In vitro activity of lascufloxacin against Streptococcus pneumoniae with mutations in the quinolone resistance-determining regions (QRDRs).Moxifloxacin: a respiratory fluoroquinolone
P2860
Q28552446-BE9B1205-FD8F-4F8F-A712-B66007102E48Q34502866-D2F4CA9F-0D9D-4162-9F7E-86B9F3AEEE5CQ34885313-9BFC66F6-95D4-47A0-90DF-596A5B68DFFAQ35168927-48D0817F-60C6-4C33-9B1B-F918C2F48C4BQ35875929-93955B00-97D9-4532-8481-C53E07B6D065Q36066098-B1C10F21-8A50-4F59-A4C3-8D459AAD7999Q36505518-050CB9DD-EAFD-40E3-96E9-92E354FB2662Q36728061-9077A013-6646-45CB-9502-D3B4978BC8A3Q36728602-8E102372-F607-4095-99B6-E6EDAAFFF754Q36817994-98CBF3C2-5CFF-45B5-B70D-C7012BBBDF1EQ37188136-10B0773D-3901-4659-9764-9ECB29AA7DFAQ37595559-EAE0EE86-1DA5-40FD-BD6B-586726BCD74EQ37733449-7352E8E9-9345-4E6D-9D06-CC5D54569972Q38692072-B0865FA6-C9B2-4A29-AE2D-4920E9FD9CE2Q39698735-67487210-EBDA-4790-AE8D-F9FEEA7C9A98Q39731893-6B5B0F8D-E832-40DB-831F-88CF56227426Q39792565-3EE8EE0B-904A-4456-8366-637B8F0AD367Q39792656-8213DAD6-152F-4B76-A7A9-D96D663E3E3AQ41822811-43D2CA2A-19AB-4A6D-9611-E3A6D84D50E4Q41854694-7CACBCC2-27ED-40DA-BA4E-5306E0BF57E4Q41887110-B24A0F81-8DEA-499B-A942-AFC6AD0F65D5Q42127654-D4D6A969-6197-4848-971E-911EF5ACCC60Q42243746-0E7DCEEC-8E18-4A03-A5CF-9ABBCDF33919Q42408812-1D8F38A0-CF70-4944-8CBF-58BBF2EBD743Q42612081-484259AD-5C0E-4FB4-B504-6A6BFFF18252Q42784718-9C8D5D00-29A7-4BDF-A4E0-973A7CD94938Q42943040-D2F44A31-87AF-444C-94BD-C75657FDE4F4Q43014021-7A4F796A-B351-49F2-A05D-E2A3D7375050Q43251107-13BCDCE2-A938-4B12-9805-1EE31025CC0CQ44883946-11524354-DBAC-4226-9EE6-A1622CF26DAAQ50028270-546896B8-FA32-4567-9469-000E7EEF421EQ57778170-1D93FEAB-F07C-4247-A0A4-DA88CA3DE036
P2860
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@en
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@nl
type
label
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@en
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@nl
prefLabel
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@en
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin.
@nl
P2860
P1476
Selection of Streptococcus pne ...... moxifloxacin and levofloxacin
@en
P2093
Karl Drlica
Xinying Li
P2860
P304
P356
10.1128/AAC.46.2.522-524.2002
P407
P50
P577
2002-02-01T00:00:00Z